SALES WORLDWIDE

$7.5 billion

+7.1% on organic basis

KEY PRODUCTS

SALES ACROSS ALL CORE BUSINESSES1

SALES ON ORGANIC BASIS*

DIAGNOSTICS

+4.4%

MEDICAL DEVICES

+9.5%

NUTRITION

+6.7%

ESTABLISHED PHARMACEUTICALS

+5.4%

NEW PRODUCT ADVANCEMENTS

U.S. APPROVALS

Amplatzer Piccolo™ Occluder
A pea-sized device that can mend the hearts of premature infants

Mitraclip™
Expanded Use
The first transcatheter device approved in the U.S. to treat advanced heart failure patients with significant secondary mitral regurgitation

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
A new catheter to help physicians treat irregular heartbeats

EUROPEAN APPROVALS4

Alinity™ci-series, our most advanced diagnostic testing technology, is being used by one of the largest reference labs in the U.S.

Abbott and the Japanese Red Cross Society enter long-term partnership for blood screening

FULL-YEAR 2019 GUIDANCE3

$3.15 to $3.25 ADJUSTED DILUTED EPS

MIDPOINT REFLECTS DOUBLE-DIGIT GROWTH

REINVENTING THE LABORATORY

Abbott and the Japanese Red Cross Society enter long-term partnership for blood screening

FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.